(1S,2R)-cis-5-Methoxy-1-methyl-2-(dimethylamino)tetralin hydrochloride

Discontinued Product

(1S,2R)-cis-5-Methoxy-1-methyl-2-(dimethylamino)tetralin hydrochloride (Cat. No. 0679) has been withdrawn from sale for commercial reasons.
Cat.No. 0679 - (1S,2R)-cis-5-Methoxy-1-methyl-2-(dimethylamino)tetralin hydrochloride
Description: Antagonist at pre- and postsynaptic sites
Datasheet
Citations
Reviews
Literature

Biological Activity

Dopamine receptor antagonist at pre- and postsynaptic sites.

Technical Data

M. Wt 255.79
Storage Store at RT

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Product Datasheets

Certificate of Analysis is currently unavailable on-line.
Please contact Customer Service

References

References are publications that support the biological activity of the product.

Johansson et al (1987) Resolved cis and trans-2-amino-5-methoxy-1-methyltetralins: central dopamine receptor agonists and antagonists. J.Med.Chem. 30 602 PMID: 3560156

View Related Products by Target

View Related Products by Product Action

View all Non-selective Dopamine Antagonists

Keywords: (1S,2R)-cis-5-Methoxy-1-methyl-2-(dimethylamino)tetralin hydrochloride, (1S,2R)-cis-5-Methoxy-1-methyl-2-(dimethylamino)tetralin hydrochloride supplier, Non-selective, Dopamine, 0679, Tocris Bioscience

Citations for (1S,2R)-cis-5-Methoxy-1-methyl-2-(dimethylamino)tetralin hydrochloride

Citations are publications that use Tocris products.

Currently there are no citations for (1S,2R)-cis-5-Methoxy-1-methyl-2-(dimethylamino)tetralin hydrochloride.

Reviews for (1S,2R)-cis-5-Methoxy-1-methyl-2-(dimethylamino)tetralin hydrochloride

There are currently no reviews for this product. Be the first to review (1S,2R)-cis-5-Methoxy-1-methyl-2-(dimethylamino)tetralin hydrochloride and earn rewards!

Have you used (1S,2R)-cis-5-Methoxy-1-methyl-2-(dimethylamino)tetralin hydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


GPCR

GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Secretin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling
Neurodegeneration

Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease
Dopamine Receptors

Dopamine Receptors Scientific Review

Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.

Parkinson's

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.

Schizophrenia

Schizophrenia Poster

Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.